Brooklyn, NY – November 7, 2018 – Brooklyn ImmunoTherapeutics, a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, and Providence Cancer Institute today announced that a poster on results of IRX-2 therapy in resectable breast cancer and head and neck cancer has been accepted for an oral presentation at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 7-11 at the Walter E. Washington Convention Center in Washington, D.C.
IRX-2 is an allogeneic, cell-derived biologic with multiple active cytokine components, including IL-2, that act on various parts of the immune system to activate the entire tumor microenvironment.
Presenter: David B. Page, MD, Assistant Member, Breast Cancer Immunotherapy, Earle A. Chiles Research Institute, a division of Providence Cancer Institute, Portland, Ore.
Title: Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma
Session: Advances in Immunotherapy of Breast and Gynecologic Cancers
Session Date and Time: Saturday, Nov. 10 from 3:35-5 p.m.
IRX-2 is a proprietary therapeutic containing numerous active cytokine components, which data suggests may restore and activate multiple immune cell types, including T cells, dendritic cells and natural killer cells, which are known to recognize and attack tumors. IRX-2 is a primary cell-derived biologic produced by stimulation of human peripheral blood mononuclear cells (PBMCs) obtained from heathy donor whole blood. Data collected to date suggest that IRX-2 reduces the immune suppression that is often seen in the cancer tumor microenvironment. This immunomodulatory activity appears to occur through the restoration of immune function and activation of a coordinated immune response against the tumor.
Brooklyn ImmunoTherapeutics (formerly IRX Therapeutics) is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies.
Our most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
For more information about the company and its clinical programs, please visit www.BrooklynITx.com.
Providence Cancer Institute, a part of Providence Health & Services, offers the latest in cancer services, including diagnostic, treatment, prevention, education, support and internationally-renowned research. The Earle A. Chiles Research Institute, a division of Providence Cancer Institute, is a world-class research facility located within the Robert W. Franz Cancer Center. The institute’s main area of investigation is cancer immunotherapy, a specialized field of study focused on triggering the immune system to destroy cancer. Learn more at www.ProvidenceOregon.org/cancer.
MacDougall Biomedical Communications